Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
Prostate cancer (PCa) is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. It emerges through the acquisition of genetic and epigenetic alterations. Epigenetic modifications include DNA methylation, histone modifications and microRNA deregulation....
| Autor principal: | |
|---|---|
| Outros Autores: | , , |
| Formato: | review |
| Idioma: | eng |
| Publicado em: |
2020
|
| Assuntos: | |
| Texto completo: | http://hdl.handle.net/10362/94246 |
| País: | Portugal |
| Oai: | oai:run.unl.pt:10362/94246 |